J&J offers $5.5bn settlement in lawsuits claiming talc link to cancer
Johnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 69,000 lawsuits in the United States alleging that its talc-based baby powder caused ovarian cancer. This agreement, announced on Monday, aims to cover nearly all outstanding talc-related cases in US federal and state courts, though it requires acceptance from 95 percent of claimants to be finalized.

Briefing Summary
AI-generatedJohnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 69,000 lawsuits in the United States alleging that its talc-based baby powder caused ovarian cancer. This agreement, announced on Monday, aims to cover nearly all outstanding talc-related cases in US federal and state courts, though it requires acceptance from 95 percent of claimants to be finalized. J&J maintains that there is no evidence linking talc to cancer, but the company discontinued sales of its talc-based baby powder in the US in 2020 and globally in 2023. The settlement does not include the United Kingdom, where a significant product liability case involving over 7,000 potential claimants is currently being heard. This resolution aims to conclude a decade-long legal battle for the pharmaceutical giant.
Article analysis
Model · rule-basedKey claims
5 extractedThe deal does not cover the United Kingdom, where a large product liability case is being adjudicated.
J&J maintains that there is no evidence that talc causes cancer.
The World Health Organization classified talc as 'probably carcinogenic to humans' in 2024.
The settlement covers about 69,000 cases in US federal and state courts, accounting for 99.75 percent of outstanding talc-related cases in the country.
Johnson & Johnson has agreed to pay $5.5bn to settle tens of thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer.